NKTR vs VERX
NKTR: A clinical-stage biotechnology company developing next-generation immunomodulatory therapies for autoimmune diseases and cancer. VERX: Vertex automates and governs transaction-based indirect tax compliance across 195 countries for enterprises, embedded into their commerce systems to handle real-time tax calculation, reporting, and digital transmission to authorities.
Side-by-side fundamentals
| Metric | NKTR | VERX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $69.32 | $11.05 | |
| Market cap as of 2026-07-23 | $2.4B | $1.8B | |
| P/E as of 2026-07-23 | n/a | 247.97 | |
| Net margin as of 2026-07-23 | -280.8% | -0.8% | VERX higher |
| Gross margin as of 2026-07-23 | +100.0% | +64.3% | NKTR higher |
| Operating margin as of 2026-07-23 | -242.0% | -1.7% | VERX higher |
| ROE as of 2026-07-23 | -45.8% | -2.5% | VERX higher |
| ROA as of 2026-07-23 | -40.3% | -0.5% | VERX higher |
| Debt / equity as of 2026-07-23 | 0.10 | 1.37 | NKTR lower |
| Revenue growth (YoY) as of 2026-07-23 | -36.2% | +11.8% | VERX higher |
| Revenue CAGR (3y) SEC XBRL | -15.7% | +15.0% | VERX higher |
| Dividend streak (yrs) SEC XBRL | n/a | 3 | |
| Beta as of 2026-07-23 | 1.13 | 0.84 | |
| 1-year return as of 2026-07-22 close | +183.2% | -68.7% | NKTR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.